understand
epidemiolog
infect
allogen
hematopoiet
stem
cell
transplant
hct
import
implement
appropri
prevent
strategi
well
effect
diagnos
treat
individu
patient
sever
group
expert
profession
organ
publish
guidelin
provid
specifi
c
recommend
prophylaxi
manag
infect
hct
includ
vaccin
mani
recommend
necessarili
base
lowqual
evid
reli
heavili
expert
opinion
guidelin
follow
blindli
understood
tool
may
help
provid
best
possibl
care
risk
factor
infect
includ
individu
characterist
eg
indic
hct
prior
infect
cmv
serostatu
particular
genet
trait
type
transplant
base
condit
regimen
stem
cell
sourc
degre
hla
homolog
immunosuppress
develop
graftversushost
diseas
gvhd
frequent
decis
contributor
infecti
morbid
mortal
differ
indic
hct
associ
infecti
risk
primari
immunodefi
cienci
pid
hemoglobinopathi
hematolog
malign
present
differ
challeng
even
hematolog
malign
risk
may
vari
depend
specifi
c
condit
patient
chronic
myelogen
leukemia
cml
acut
myeloid
leukemia
aml
chronic
lymphocyt
leukemia
cll
present
differ
risk
base
biolog
diseas
prior
treatment
factor
consid
assess
individu
patient
prior
infect
must
consid
histori
infect
colon
multidrugresist
organ
mdro
like
carbapenemresist
enterobacteria
cre
extendedspectrum
betalactamas
esbl
produc
gramneg
bacteria
vancomycinresist
enterococcu
vre
methicillinresist
staphylococcu
aureu
mrsa
implic
regard
optim
manag
fever
neutropenia
common
complic
hct
transplant
candid
routin
screen
serolog
evid
latent
infect
may
reactiv
hsv
vzv
cmv
ebv
hepat
b
c
toxoplasmosi
discuss
later
chapter
transplant
center
perform
screen
tuberculosi
tuberculin
skin
test
tst
interferongamma
releas
assay
igra
least
patient
consid
signifi
cant
risk
diseas
prior
invas
fungal
infect
may
reactiv
follow
transplant
secondari
prophylaxi
requir
even
activ
fungal
infect
report
control
howev
case
progress
prior
aspergillosi
transplant
myeloabl
condit
prolong
neutropenia
cytomegaloviru
cmv
diseas
graftversushost
diseas
gvhd
risk
factor
correl
nativ
adapt
immun
better
understood
genet
associ
come
light
evid
donor
haplotyp
gene
encod
tolllik
receptor
protein
associ
increas
risk
invas
aspergillosi
hct
recipi
mutat
gene
encod
mannosebind
lectin
mbl
associ
increas
risk
infect
neutrophil
recoveri
follow
myeloabl
transplant
polymorph
may
import
infect
direct
infl
uenc
risk
develop
gvhd
differ
genotyp
activ
killer
immunoglobulinlik
receptor
akir
donor
found
protect
cmv
reactiv
mani
associ
preliminari
requir
data
confi
rmed
hold
promis
individu
approach
infecti
prophylaxi
practic
standpoint
help
consid
three
distinct
period
transplant
preengraft
neutrophil
recoveri
earli
postengraft
engraft
day
late
postengraft
day
framework
origin
myeloabl
transplant
emin
pragmat
preengraft
phase
may
accompani
profound
neutropenia
signifi
cant
mucos
result
increas
risk
bacteri
infect
resid
gastrointestin
fl
ora
candidiasi
aspergillosi
case
prolong
neutropenia
herp
simplex
viru
reactiv
engraft
neutropenia
longer
factor
mani
infect
relat
profound
defect
cellular
immun
caus
condit
regimen
immunosuppress
administ
prevent
gvhd
cmv
reactiv
develop
acut
gvhd
treatment
play
central
role
time
day
landmark
deriv
standard
time
immunosuppress
eg
cyclosporin
tacrolimu
frequent
taper
infect
point
would
primarili
relat
lack
immun
reconstitut
absenc
gvhd
becom
progress
less
common
allogen
stem
cell
transplant
sever
characterist
transplant
infl
uenc
risk
infect
condit
prepar
regimen
sourc
stem
cell
degre
hla
ident
donor
recipi
prophylact
strategi
adopt
prevent
gvhd
use
cell
deplet
immunosuppress
medic
tabl
summar
impact
factor
infect
match
ucb
transplant
focus
three
loci
hlaa
hlab
major
ucb
transplant
mismatch
least
one
locu
often
two
among
transplant
mismatch
two
loci
mismatch
hlac
associ
highest
risk
mortal
degre
mismatch
donor
recipi
affect
infecti
risk
mainli
likelihood
gvhd
gvhd
usual
result
infect
prevent
gvhd
mismatch
transplant
potent
immunosuppress
may
requir
increas
risk
infect
also
possibl
immun
reconstitut
proce
slowli
even
immunosuppress
regimen
urd
hct
factor
may
result
increas
risk
infect
associ
cell
immunodefi
cienci
like
cmv
pneumocysti
jirovecii
pneumonia
pcp
epsteinbarr
viru
ebv
relat
posttranspl
lymphoprolif
disord
ptld
howev
provid
number
stem
cell
administ
usual
kg
neutrophil
recoveri
proce
standard
pace
increas
risk
neutropeniarel
infect
problem
ucb
transplant
includ
markedli
decreas
stem
cell
dose
often
kg
result
prolong
neutropenia
week
attend
risk
bacteri
fungal
infect
addit
cord
blood
antigenspecifi
c
memori
cell
expand
thymusindepend
fashion
provid
protect
virus
opportunist
pathogen
result
high
frequenc
late
sever
infect
follow
cord
transplant
even
neutropen
period
shorten
coadministr
stem
cell
thirdparti
donor
stem
cell
may
given
use
bone
marrow
gcsfmobil
peripher
blood
stem
cell
pbsc
ucb
frequent
bone
marrow
result
prolong
neutropenia
compar
pbsc
increas
infect
neutropenia
expect
howev
multicent
random
trial
compar
peripher
blood
stem
cell
bone
marrow
unrel
donor
show
differ
relaps
infecti
mortal
group
confi
rmed
chronic
gvhd
common
mobil
pbsc
particular
featur
ucd
transplant
discuss
preced
paragraph
manipul
stem
cell
immunosuppress
drug
combin
gvhd
may
prevent
decreas
amount
donor
cell
limit
cell
function
immunosuppress
agent
stem
cell
whether
bone
marrow
peripheri
may
administ
unmanipul
sometim
call
cell
replet
enrich
select
also
call
cell
deplet
unmanipul
bone
marrow
pbsc
use
dose
cell
administ
graft
vari
kg
bone
marrow
use
kg
pbsc
use
reduct
amount
cell
log
possibl
haploident
transplant
regimen
cell
given
still
result
detect
immun
reconstitut
start
month
transplant
cell
deplet
may
minim
altogeth
prevent
gvhd
may
result
prolong
immunodefici
depend
degre
deplet
unmanipul
product
use
cell
deplet
may
attain
vivo
use
alemtuzumab
atg
agent
produc
profound
deplet
cell
vivo
long
halflif
make
still
present
activ
recipi
stem
cell
product
administ
vitro
vivo
cell
deplet
use
one
varieti
immunosuppress
regimen
given
prevent
gvhd
eg
tacrolimu
methotrex
tacrolimu
plu
mycophenol
mofetil
cyclosporin
sirolimu
posttranspl
cyclophosphamid
random
control
trial
document
infect
patient
random
moder
cell
deplet
group
receiv
pharmacolog
immunosuppress
cell
deplet
vivo
alemtuzumab
associ
increas
risk
infect
possibl
differ
pharmacolog
regimen
may
result
differ
infecti
risk
adequ
studi
preliminari
evid
suggest
sirolimusbas
regimen
may
result
less
cmv
reactiv
posttranspl
cyclophosphamid
result
rel
decreas
risk
ptld
categori
may
combin
sever
way
compound
risk
infect
variat
consid
design
regimen
antiinfect
prophylaxi
consid
individu
patient
may
infect
gvhd
import
caus
nonrelaps
mortal
follow
hct
frequent
complic
infect
gvhd
categor
acut
chronic
base
time
onset
acut
gvhd
develop
day
character
gastrointestin
diseas
secretori
diarrhea
nausea
vomit
liver
dysfunct
skin
rash
stage
gvhd
skin
gut
liver
combin
give
grade
iiv
sever
diseas
acut
gvhd
grade
iiiiv
associ
signifi
cant
mortal
treatment
choic
highdos
system
corticosteroid
gvhd
associ
signifi
cant
immun
dysregul
frequent
accompani
cmv
reactiv
combin
disrupt
gi
mucosa
sometim
skin
highdos
corticosteroid
addit
immunosuppress
agent
concurr
given
like
tacrolimu
mmf
constitut
highrisk
set
infect
bacteri
fungal
viral
infect
common
circumst
chronic
graftversushost
diseas
cgvhd
tradit
defi
ned
chronolog
gvhd
start
day
classifi
ed
base
relat
prior
gvhd
progress
acut
gvhd
continu
day
quiescent
period
time
patient
free
gvhd
de
novo
chronic
gvhd
fi
rst
manifest
gvhd
extens
limit
extens
reformul
clinic
limit
clinic
extens
clinic
syndrom
typic
chronic
gvhd
quit
distinct
acut
form
new
classifi
cation
focus
clinic
characterist
diseas
well
time
increasingli
use
standpoint
infecti
diseas
import
consider
presenc
chronic
gvhd
associ
high
risk
infect
multipl
immun
defect
describ
chronic
gvhd
involv
humor
cellular
immun
well
function
hyposplen
besid
abnorm
result
delay
immun
reconstitut
poor
respons
immun
risk
infect
increas
treatment
extens
cgvhd
typic
includ
system
corticosteroid
varieti
steroidspar
agent
notabl
cgvhd
welldocu
risk
pneumococc
infect
fungal
infect
late
cmv
diseas
howev
type
infect
common
cgvhd
particularli
fi
rst
month
gvhd
control
corticosteroid
call
steroid
refractori
current
univers
accept
standard
treatment
situat
import
infecti
diseas
standpoint
patient
usual
treat
varieti
highli
immunosuppress
regimen
eg
atg
cyclophosphamid
mmf
infl
iximab
daclizumab
alefacept
alemtuzumab
sirolimu
visilizumab
denileukin
diftitox
other
result
wide
array
infecti
complic
reactiv
cmv
common
fungal
infect
epsteinbarr
virusrel
ptld
well
human
herpesviru
adenoviru
control
studi
support
particular
infect
prevent
strategi
period
increas
immunosuppress
author
emphas
earli
use
prophylact
antibiot
antifung
essenti
part
success
approach
problem
unfortun
condit
control
trial
unlik
perform
differ
center
decid
particular
approach
close
monitor
versu
prophylaxi
base
local
experi
publish
case
seri
follow
section
epidemiolog
bacteri
fungal
viral
parasit
diseas
discuss
implic
prophylaxi
manag
mention
immun
transplant
recipi
well
caregiv
immedi
contact
discuss
chap
risk
epidemiolog
bacteri
infect
allogen
hct
earli
bacteri
infect
preengraft
approxim
hct
recipi
experi
least
one
episod
bacteremia
fi
rst
week
similar
proport
engraft
infect
usual
relat
either
neutropenia
subsequ
bacteri
transloc
gi
mucosa
mucos
barrier
injuri
laboratoryconfi
rmed
bloodstream
infect
mbilcbi
intravascular
cathet
central
lineassoci
bloodstream
infect
clabsi
rel
frequenc
gramposit
gramneg
infect
neutropenia
vari
differ
seri
use
prophylact
antibiot
center
frequent
gramposit
isol
viridan
group
streptococcu
may
function
condit
regimen
patient
popul
enterococcu
faecium
frequent
vre
anoth
gramposit
organ
tend
caus
bloodstream
infect
rel
earli
although
seem
rather
institut
depend
gramneg
bacteria
commonli
enterobacteriacea
infect
gener
relat
disrupt
gi
mucosa
due
prepar
regimen
role
reduc
divers
microbiota
subsequ
bacteri
domin
ultim
bacteremia
area
intens
studi
risk
bacteremia
neutropenia
may
decreas
use
prophylact
antibiot
shown
multipl
studi
year
recommend
use
antibiot
becom
part
practic
guidelin
recent
clear
whether
recommend
continu
amidst
increas
concern
role
antibioticinduc
decreas
microbiom
divers
outcom
hct
regard
interest
fl
uoroquinolon
seem
less
detriment
effect
biodivers
fecal
fl
ora
betalactam
levofl
oxacin
dose
mgd
patient
go
profoundli
neutropen
longer
week
current
recommend
idsa
follow
engraft
larg
studi
sloan
ketter
cancer
center
risk
factor
postengraft
bacteremia
includ
acut
gvhd
renal
dysfunct
hepat
dysfunct
neutropenia
enterococcu
vre
coagulaseneg
staphylococcu
common
gramposit
isol
enterobacteriacea
nonfer
gramneg
bacteria
includ
pseudomona
stenotrophomona
acinetobact
possibl
relat
indwel
cathet
common
gramneg
isol
bacteremia
follow
engraft
often
happen
set
patient
complic
clinic
cours
acut
gvhd
multipl
medic
problem
els
cathet
relat
daili
bath
chlorhexidineimpregn
washcloth
decreas
risk
acquisit
mdro
develop
hospitalacquir
bloodstream
infect
transplant
recipi
random
trial
practic
consid
everi
transplant
program
advantag
disadvantag
activ
screen
colon
resist
pathogen
adequ
studi
hct
recipi
like
local
epidemiolog
determin
whether
screen
effi
caciou
costeffect
approach
either
prevent
infect
improv
outcom
retrospect
studi
vre
bacteremia
sloan
ketter
cancer
center
show
vre
carriag
predict
subsequ
vre
bacteremia
fail
detect
pathogen
mani
patient
perform
surveil
cultur
resist
organ
vulner
patient
popul
part
cdc
recommend
manag
multidrugresist
organ
healthcar
set
vigor
advoc
expert
earli
late
beyond
day
pneumococc
diseas
report
late
infect
strongli
associ
activ
cgvhd
attribut
inadequ
antibodi
product
function
hyposplen
vaccin
pneumonia
given
hct
recipi
start
month
transplant
use
conjug
vaccin
see
chap
detail
four
dose
vaccin
result
enhanc
antibodi
respons
toler
side
effect
antibiot
prophylaxi
pneumonia
prophylaxi
adult
activ
cgvhd
recommend
although
weak
evid
support
effi
caci
penicillin
vk
safe
well
toler
local
pattern
penicillin
resist
may
make
antibiot
eg
trimethoprim
sulfamethoxazol
azithromycin
levofl
oxacin
prefer
although
longterm
safeti
well
establish
late
bacteri
infect
often
involv
respiratori
tract
pneumonia
common
caus
fatal
late
infect
chronic
gvhd
risk
factor
commonli
identifi
ed
besid
pneumonia
multipl
pathogen
report
nocardia
also
tend
occur
late
patient
cgvhd
mycobacteri
infect
uncommon
diffi
cult
diagnos
risk
factor
develop
activ
tb
includ
gvhd
corticosteroid
treatment
total
bodi
irradi
tbi
need
univers
test
tuberculosi
controversi
given
unknown
sensit
specifi
citi
test
popul
fact
tuberculosi
rel
uncommon
complic
hct
albeit
still
approxim
three
time
higher
gener
popul
invas
candidiasi
follow
prior
colon
favor
condit
yeast
disrupt
gi
mucosa
chemotherapi
acut
gvhd
overgrowth
presenc
broadspectrum
antibiot
andor
presenc
indwel
cathet
cathet
seem
main
risk
factor
case
c
parapsilosi
earli
studi
show
fl
uconazol
preengraft
period
could
decreas
incid
invas
candidiasi
accordingli
fl
uconazol
recommend
part
standard
prophylact
regimen
preengraft
period
preval
use
fl
uconazol
result
substanti
decreas
incid
infect
caus
c
albican
rel
increas
incid
speci
candida
decreas
suscept
agent
eg
c
glabrata
c
krusei
invas
aspergillosi
occur
specifi
c
risk
period
follow
hct
fi
rst
peak
around
time
neutropenia
preengraft
second
peak
day
time
acut
gvhd
treatment
third
peak
late
transplant
usual
midst
activ
treat
cgvhd
figur
varieti
risk
factor
invas
aspergillosi
identifi
ed
year
consist
found
signifi
cant
multivari
analys
acut
gvhd
chronic
extens
gvhd
cmv
diseas
system
corticosteroid
almost
alway
present
part
treatment
acut
chronic
gvhd
nonaspergillu
mold
infect
eg
fusariosi
mucormycosi
scedosporiosi
sometim
refer
emerg
mold
infect
report
increas
frequenc
increas
use
prophylaxi
activ
aspergillu
would
expect
result
rel
increas
opportunist
mycos
like
mucormycosi
consid
divers
fungal
infect
transplant
current
antifung
armamentarium
controversi
antifung
prophylaxi
appropri
point
transplant
instanc
although
fl
uconazol
safe
wellestablish
intervent
preengraft
period
myeloabl
transplant
reason
question
necessari
transplant
condit
regimen
result
shorter
neutropenia
micafungin
show
equival
fl
uconazol
random
control
trial
question
kind
transplant
patient
would
benefi
appli
regard
durat
antifung
prophylaxi
fl
uconazol
day
posttranspl
associ
improv
surviv
mainli
due
decreas
incid
system
candidiasi
uncertain
whether
strategi
use
patient
receiv
select
subgroup
consid
higher
risk
similarli
reason
question
indic
fl
uconazol
period
main
fungal
infect
aspergillosi
sever
random
control
trial
compar
fl
uconazol
anoth
azol
activ
mold
itraconazol
voriconazol
posaconazol
either
standard
posttranspl
prophylaxi
period
increas
risk
gener
conclus
trial
aspergillusact
drug
inde
effect
fl
uconazol
prevent
ia
benefi
surviv
context
clinic
trial
care
monitor
galactomannan
antigen
hard
demonstr
asbmtebmt
guidelin
recommend
posaconazol
voriconazol
antifung
prophylaxi
set
gvhd
micafungin
set
prolong
neutropenia
note
posaconazol
prophylaxi
superior
fl
uconazol
itraconazol
improv
surviv
prolong
neutropenia
nontranspl
patient
even
option
moldact
prophylaxi
posaconazol
delayedreleas
tablet
intraven
posaconazol
new
agent
isavuconazol
infect
allogen
hct
viral
infect
remain
challeng
newer
transplant
modal
result
sever
prolong
cell
immunodefici
current
antivir
armamentarium
limit
multipl
latent
virus
may
reactiv
follow
hct
role
monitor
pcr
well
defi
ned
mainli
cmv
latent
viral
reactiv
particular
concern
recipi
cord
celldeplet
transplant
tabl
present
summari
section
member
herpesviru
famili
caus
signific
diseas
transplant
includ
vzv
ebv
cmv
posttranspl
complic
well
defi
ned
although
multipl
associ
describ
infect
diseas
primari
effus
lymphoma
kaposi
sarcoma
occur
infrequ
hct
may
reactiv
follow
prepar
regimen
complic
chemotherapyinduc
mucos
customari
administ
prophylaxi
acyclovir
valacyclovir
least
engraft
patient
common
recurr
longterm
suppress
may
appropri
vzv
predict
reactiv
follow
transplant
approxim
fi
rst
year
either
shingl
multidermatom
dissemin
even
without
rash
zoster
sine
herpet
patient
risk
vzv
reactiv
use
longterm
acyclovir
safe
prevent
occurr
vzv
diseas
current
recommend
least
year
follow
hct
cmv
remain
latent
varieti
human
cell
cmvseroposit
hct
recipi
risk
cmv
reactiv
diseas
transplant
term
cmv
infect
use
denot
presenc
cmv
blood
detect
pcr
antigenemia
follow
reactiv
cmv
may
caus
diseas
typic
form
pneumonia
andor
gastrointestin
diseas
commonli
coliti
cmv
diseas
like
retin
cn
involv
rare
hct
describ
retin
associ
high
cmv
viral
load
sometim
context
chronic
gvhd
cn
diseas
enceph
ventricul
sometim
resist
viru
cn
risk
reactiv
may
relat
presenc
cmvspecifi
c
immun
donor
rate
cmv
infect
donorrecipi
dr
pair
often
follow
progress
r
r
r
r
suggest
cmvspecifi
c
memori
cell
administ
stem
cell
may
play
role
prevent
reactiv
diseas
cmv
infect
diseas
cmvseroneg
recipi
seroneg
donor
rare
leucodeplet
cmvneg
blood
product
use
everi
transplant
program
must
decid
strategi
monitor
cmv
prevent
diseas
depend
varieti
factor
either
univers
prophylaxi
ganciclovir
day
preemptiv
strategi
weekli
monitor
earli
therapi
may
use
approach
result
similar
overal
mortal
compar
random
control
trial
univers
prophylaxi
follow
case
late
cmv
diseas
late
cmv
diseas
emerg
signifi
cant
problem
occur
patient
close
monitor
transplant
center
risk
factor
includ
lymphopenia
chronic
gvhd
prevent
late
cmv
diseas
may
accomplish
either
prophylaxi
valganciclovir
preemptiv
approach
weekli
cmv
pcr
monitor
effect
cmv
serostatu
donor
recipi
overal
surviv
complex
review
see
chap
ptld
spectrum
lymphoid
prolifer
may
happen
solid
organ
allogen
stem
cell
transplant
usual
alway
driven
ebv
patholog
spectrum
goe
polymorph
polyclon
tissu
infi
ltration
lymphocyt
monomorph
involv
highgrad
b
cell
lymphoma
allogen
hct
prolifer
cell
may
donor
commonli
recipi
origin
disord
typic
relat
insuffi
cient
abnorm
cell
respons
ebv
accordingli
common
set
hlamismatch
transplant
cell
deplet
intens
immunosuppress
treatment
gvhd
case
follow
use
alemtuzumab
vivo
cell
deplet
gvhd
prophylaxi
despit
fact
also
result
deplet
b
cell
earlier
report
associ
rel
less
risk
interestingli
use
posttranspl
cyclophosphamid
prevent
gvhd
seem
associ
lower
risk
ptld
monitor
ebv
viral
load
quantit
pcr
recommend
transplant
consid
high
risk
preemptiv
manag
increas
ebv
viral
load
patient
risk
associ
good
outcom
although
clear
exactli
treatment
given
ctpet
may
use
local
area
amen
biopsi
figur
acquir
earli
life
may
caus
roseola
infantum
nonspecifi
c
febril
ill
frequent
reactiv
follow
hct
use
quantit
pcr
often
detect
peripher
blood
week
transplant
time
reactiv
seem
asymptomat
number
associ
rash
delay
engraft
gvhd
thrombocytopenia
increas
overal
mortal
well
actual
clinicopatholog
entiti
hepat
pneumon
enceph
describ
possibl
common
caus
infecti
enceph
hct
seem
particularli
frequent
cord
blood
transplant
case
enceph
tend
accompani
higher
viral
load
plasma
role
systemat
monitor
plasma
unknown
time
reactiv
seem
much
common
diseas
attempt
use
preemptiv
strategi
use
foscarnet
success
european
confer
infect
leukemia
propos
evidencebas
guidelin
address
diagnost
therapeut
uncertainti
relat
infect
respiratori
virus
heterogen
group
viru
respons
upper
acut
respiratori
infect
normal
host
result
signifi
cant
morbid
mortal
hct
particularli
fi
rst
month
follow
transplant
even
asymptomat
carriag
respiratori
virus
time
transplant
report
result
increas
risk
unfavor
outcom
besid
respiratori
syncyti
viru
rsv
infl
uenza
parainfl
uenza
viru
piv
rhinoviru
adenoviru
newli
identifi
ed
virus
includ
metapneumoviru
coronaviru
bocaviru
emerg
signifi
cant
pathogen
infect
present
signifi
cant
risk
acut
long
term
acut
infect
hct
recipi
risk
develop
viral
pneumonia
sometim
progress
respiratori
insuffi
cienci
mechan
ventil
death
also
risk
concomit
secondari
bacteri
fungal
infect
associ
increas
mortal
longterm
seem
associ
earli
infect
preday
virus
notabl
piv
rsv
later
develop
chronic
airfl
ow
obstruct
signifi
cant
risk
factor
overal
progress
infect
upper
respiratori
tract
lung
seem
lymphopenia
corticosteroid
use
seem
contribut
progress
pneumonia
rsv
parainfl
uenza
infect
infl
uenza
see
tabl
besid
role
among
communityacquir
respiratori
viru
adenoviru
may
caus
diseas
transplant
recipi
follow
reactiv
gastrointestin
tract
follow
dissemin
endorgan
damag
de
novo
acquisit
adenoviru
may
also
result
dissemin
diseas
type
human
adenoviru
differ
tropism
possibl
vari
suscept
antivir
agent
caus
varieti
diseas
includ
upper
lower
respiratori
tract
infect
coliti
hemorrhag
cystiti
hc
nephropathi
cn
diseas
system
adenoviru
diseas
seem
common
children
particularli
recipi
cord
blood
celldeplet
transplant
patient
gvhd
treatment
highdos
corticosteroid
also
risk
figur
studi
document
sustain
high
level
adenoviremia
associ
diseas
known
yet
whether
preemptiv
approach
cidofovir
success
prevent
dissemin
diseas
death
bk
viru
infect
human
age
predict
reactiv
patient
follow
hct
caus
hemorrhag
cystiti
hc
minor
detect
high
level
bk
peripher
blood
seem
correl
presenc
bkinduc
hc
larg
studi
fred
hutchinson
cancer
research
center
fhcrc
associ
found
bk
virusassoci
hc
lymphopenia
corticosteroid
use
gvhdthe
typic
risk
factor
viral
infect
hct
contrast
smaller
studi
found
associ
gvhd
pathogenesi
diseas
remain
unexplain
bkinduc
nephropathi
common
problem
kidney
transplant
remain
infrequ
hct
seem
relat
profound
immunosuppress
bk
pneumon
also
describ
distinctli
rare
jc
viru
also
acquir
peopl
childhood
immunocompromis
host
may
caus
enceph
jc
enceph
previous
call
progress
multifoc
leukoencephalopathi
pml
multipl
area
demyelin
without
edema
detect
mri
studi
suggest
detect
viral
load
hct
may
common
current
thought
ascertain
risk
factor
diseas
diffi
cult
transplant
recipi
may
condit
known
associ
also
receiv
medic
like
mmf
rituximab
brentuximab
associ
pml
even
absenc
allohct
pcp
opportunist
infect
patient
profound
cellular
immunodefi
cienci
prophylaxi
recommend
hct
rel
uncommon
patient
transplant
sever
seri
case
seem
occur
rel
late
discontinu
prophylaxi
period
intens
immunosuppress
treatment
gvhd
hypoxemia
characterist
present
atyp
radiolog
manifest
includ
nodular
infi
ltrate
pleural
effus
contrast
typic
interstiti
pneumon
describ
frequent
presenc
copathogen
prefer
prophylaxi
trimethoprimsulfamethoxazol
tmpsmx
sever
dose
regimen
effect
one
singlestrength
tablet
daili
one
doublestrength
tablet
daili
one
doublestrength
tablet
three
timesweek
tmp
smx
may
poorli
toler
hematolog
toxic
skin
rash
andor
gastrointestin
toxic
unclear
prophylaxi
choic
tmp
smx
use
aerosol
pentamidin
conveni
obviat
problem
complianc
less
toxic
dapson
better
toler
atovaquon
howev
reportedli
associ
failur
dapson
dapson
seem
effect
well
toler
one
studi
anoth
given
three
time
per
week
dapson
given
patient
defi
cienci
methemoglobinemia
wellknown
complic
dapson
consid
presenc
unexplain
short
breath
atovaquon
suspens
mgd
may
use
publish
experi
hsct
recipi
limit
atovaquon
expens
poor
toler
made
complianc
patient
diffi
cult
absorpt
better
presenc
signifi
cant
amount
fat
breakthrough
well
document
figur
pcp
prophylaxi
recommend
least
immunosuppress
stop
unclear
much
longer
continu
case
toxoplasmosi
hct
repres
reactiv
although
rare
case
transmiss
bone
marrow
transplant
suspect
recipi
test
antitoxoplasma
igg
antibodi
found
posit
prophylaxi
recommend
rare
case
toxoplasmosi
hct
occur
seroneg
recipi
diseas
tend
occur
within
fi
rst
month
transplant
happen
later
presenc
persist
immunosuppress
risk
toxoplasmosi
vari
type
transplant
immunosuppress
cord
blood
use
atg
found
risk
factor
diseas
prospect
studi
case
anoth
seri
occur
urd
mismatch
transplant
tmpsmx
given
pcp
prophylaxi
consid
adequ
prevent
toxoplasmosi
although
case
hct
recipi
receiv
best
altern
patient
intoler
tmpsmx
unknown
dapson
atovaquon
show
effi
caci
hivinfect
patient
increas
experi
hct
although
failur
report
regimen
includ
clindamycin
pyrimethamin
leucovorin
pyrimethamin
sulfadiazin
pyrimethamin
sulfadoxin
leucovorin
reliabl
quantit
pcr
assay
avail
frequent
monitor
preemptiv
treatment
may
appropri
sinc
pcrdetect
reactiv
seem
preced
symptom
day
retrospect
data
suggest
strategi
may
result
improv
outcom
summari
infect
follow
hct
frequent
relat
risk
factor
caus
procedur
neutropenia
mucos
predispos
bacteri
infect
prolong
neutropenia
increas
likelihood
invas
fungal
infect
gvhd
treatment
creat
import
easili
identifi
abl
risk
period
varieti
infecti
complic
particularli
mold
infect
profound
prolong
cell
immunodefi
cienci
present
celldeplet
cord
blood
transplant
main
risk
factor
viral
problem
like
dissemin
adenoviru
diseas
ebvrel
ptld
besid
procedurerel
risk
factor
individu
characterist
start
investig
understood
futur
epidemiolog
basic
studi
like
result
truli
person
prophylact
regimen
increas
unquestion
benefi
ts
antimicrobi
prophylaxi
reduc
cost
direct
indirect
associ
lifesav
practic
